News stories about Aptevo Therapeutics (NASDAQ:APVO) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aptevo Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.1240632869406 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. Piper Jaffray Companies reissued an “overweight” rating and issued a $6.00 price target on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.
Shares of Aptevo Therapeutics (NASDAQ APVO) opened at $4.18 on Monday. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.50. The company has a quick ratio of 7.67, a current ratio of 7.76 and a debt-to-equity ratio of 0.19.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.